FDA approves Firvanq for treatment of C. difficile associated diarrhea

Wilmington, MA pharmaceutical company, CutisPharma announced today that the US Food and Drug Administration (FDA) has approved FIRVANQa (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. "We are pleased to announce the FDA approval of FIRVANQ," said Neal I. Muni, MD, MSPH, Chief Executive Officer of ["]

The post FDA approves Firvanq for treatment of C. difficile associated diarrhea appeared first on Outbreak News Today.